JP2019533645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533645A5
JP2019533645A5 JP2019514781A JP2019514781A JP2019533645A5 JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5 JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5
Authority
JP
Japan
Prior art keywords
protein
agents
protein nanocage
nanocage
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052079 external-priority patent/WO2018053434A1/en
Publication of JP2019533645A publication Critical patent/JP2019533645A/ja
Publication of JP2019533645A5 publication Critical patent/JP2019533645A5/ja
Pending legal-status Critical Current

Links

JP2019514781A 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ Pending JP2019533645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395852P 2016-09-16 2016-09-16
US62/395,852 2016-09-16
PCT/US2017/052079 WO2018053434A1 (en) 2016-09-16 2017-09-18 Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Publications (2)

Publication Number Publication Date
JP2019533645A JP2019533645A (ja) 2019-11-21
JP2019533645A5 true JP2019533645A5 (enExample) 2020-10-08

Family

ID=60002019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514781A Pending JP2019533645A (ja) 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ

Country Status (4)

Country Link
US (1) US11090391B2 (enExample)
EP (1) EP3512563A1 (enExample)
JP (1) JP2019533645A (enExample)
WO (1) WO2018053434A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503704A (zh) * 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
WO2019222400A2 (en) * 2018-05-15 2019-11-21 Dnalite Therapeutics, Inc. Mucus-penetrating peptides, delivery vehicles and methods of therapy
JP2022504648A (ja) * 2018-10-10 2022-01-13 ユニヴァーシティ オブ ワシントン 高ポリマー密度バイオコンジュゲート組成物及び関連方法
US12577292B2 (en) * 2019-03-07 2026-03-17 Kyungpook National University Industry-Academic Cooperation Foundation Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
KR20220057542A (ko) * 2019-09-05 2022-05-09 아지노모토 가부시키가이샤 펩타이드 내포 페리틴
US20240148898A1 (en) * 2019-11-01 2024-05-09 Cellemedy Co., Ltd Protein fused with molecule capable of binding to immune checkpoint molecule and use of same
EP4053157A4 (en) * 2019-11-01 2023-12-27 Cellemedy Co., Ltd PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE
US20240150417A1 (en) * 2019-11-01 2024-05-09 Cellemedy Co.,Ltd Disease antigen-fused protein, and use thereof
KR102658825B1 (ko) * 2020-10-23 2024-04-19 경북대학교 산학협력단 Pd-l1 결합 펩타이드 1을 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用
CN115160559B (zh) * 2021-04-02 2024-02-02 杭州宜生医药科技发展有限公司 一种peg化雷帕霉素化合物及其制备方法与应用
WO2024228598A1 (ko) * 2023-05-04 2024-11-07 경북대학교 산학협력단 Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN119326734B (zh) * 2024-12-17 2025-06-06 浙江大学 一种铁蛋白纳米颗粒及其药物递送系统的组装方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
KR920003787B1 (ko) 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
AU770643B2 (en) 1998-08-28 2004-02-26 Uropath Pty Ltd Method of diagnosis of prostate cancer
AU3007200A (en) 1999-02-26 2000-09-14 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
US8575359B2 (en) 2006-04-04 2013-11-05 The Regents Of The University Of California Acid-sensitive linkers for drug delivery
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
JPWO2010029947A1 (ja) * 2008-09-09 2012-02-02 国立大学法人京都大学 造影剤組成物及びその製造方法
JP2014518842A (ja) * 2011-02-25 2014-08-07 サウス ダコタ ステート ユニバーシティー ポリマーコンジュゲートタンパク質ミセル
RU2631599C2 (ru) * 2011-12-14 2017-09-25 Дзе Джонс Хопкинс Юниверсити Наночастицы, легче проникающие в слизистую оболочку или вызывающие меньше воспаления
CA2921493A1 (en) 2012-08-21 2014-02-27 Brown University Ferritin-based tumor targeting agent, and imaging and treatment methods
WO2016048246A1 (en) 2014-09-25 2016-03-31 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

Similar Documents

Publication Publication Date Title
AU2021282425B2 (en) Bioorthogonal compositions
US12611461B2 (en) Bioorthogonal compositions
KR101941318B1 (ko) 거대 분자
US20180085321A1 (en) Solid nanoparticle with inorganic coating
JP2010513526A5 (enExample)
JP7102005B2 (ja) 改善されたハイブリッドテロデンドリマー
JP2012532185A5 (enExample)
JP2014512409A (ja) 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
US20210100910A1 (en) Macromolecules
JP2017119721A (ja) 併用療法用ナノ粒子
JP2016509586A5 (enExample)
EP3883934A1 (en) Therapeutic dendrimer
KR20220134569A (ko) 8-클로로-n-(4-(트리플루오로메톡시)페닐)퀴놀린-2-아민의 비정질 고체 분산체
JP2021523912A5 (enExample)
CN116133693B (zh) 载药的大分子及其制备方法
JP2023500602A (ja) ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。
JP2026500527A (ja) 脂質化合物ならびにその製造方法及び使用方法
CN111373246A (zh) 包括硼替佐米的聚合物纳米颗粒
US9861707B2 (en) Treating bladder tumor cells using fibronectin attachment protein as a target
HK40118230A (en) Bioorthogonal compositions
CN120383728A (zh) 组织高粘附性聚β氨酯、载药纳米粒及其制备方法和应用
WO2024124148A1 (en) Lipid compounds and methods of making and use thereof
박주호 Design and therapeutic evaluation of heparin based bioconjugate for oral delivery and antiangiogenic therapy
JP2009545619A5 (enExample)